FDA grants Orphan Drug Designation for glioma imaging agent
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallMelbourne (Australia) – 6 October 2020. Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that the United States Food and Drug Administration (FDA) has 18 18 granted Orphan Drug Designation (ODD) for O-(2-[ F]fluoroethyl)-L-tyrosine ( F-FET), for the positron emission tomography (PET) imaging of glioma, a type of brain tumour. The granting of 18 an ODD for F-FETquali
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix submits NDA to US FDA for Prostate Cancer Imaging
- Strategic Collaboration with Varian for Prostate Imaging
- IRE Distribution Partnership for Prostate Cancer Imaging
- FDA grants orphan drug designation for TLX102
- Report for half-year to 30 June 2020
Later from Telix Pharmaceuticals
- App 4C and Activities Report for September 2020 Quarter
- Strategic Licence and Partnership for Greater China Market
- Investor Briefing - Asia Strategy
- NDA for Prostate Cancer Imaging accepted by US FDA
- Prostate Cancer Therapy FDA Meeting Update
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals